EUVIMEDEUVIMED entdecken
Crossref

Interleukin‐13 as a promising therapeutic target for alopecia areata associated with atopic dermatitis

Naoki Oiso iD

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Naoki Oiso. Beteiligte Einrichtung: Department of Dermatology, Kindai University Nara Hospital, Ikoma, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Alopecia Areata. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alopecia areata (AA) is a chronic immune-mediated hair follicle disease, regarded virtually as a type 1 inflammatory disease. Atopic dermatitis (AD) is a chronic inflammatory skin disease as a type 2 inflammatory disease. AA and AD usually compromise quality of life (QoL). Patients with AA have a higher prevalence of AD and vice versa, indicating that AA and AD share pathogenetic cascades. Atopic dermatitis can be categorized into extrinsic and intrinsic types. Extrinsic AD is associated with skin barrier dysfunction and high total serum IgE levels, and intrinsic AD is related to relatively normal skin barrier function and normal total IgE values.1 AA is caused by immune privilege collapse at the hair follicle and activation of autoreactive cytotoxic CD8+ T cells. Recently, involvement of type 2 immunity has been revealed in patients with AA and extrinsic AD, indicating different immunological states between non-atopic AA and typical atopic AA.1 Severity of Alopecia Tool (SALT) and Severity strata for Eczema Area and Severity Index (EASI) scores are significantly correlated with AA patients with extrinsic AD.1 Dupilumab, a humanized IgG4 monoclonal antibody targeting interleukin-4 (IL-4) and IL-13 signaling via inhibition of the IL-4 receptor alpha chain, shows dual efficacy for AD and AA in patients with extrinsic AD.1 Thus, it is supposed that inhibitors for IL-4 and/or IL-13 signaling would be effective for typical atopic AA. AA and AD are associated with genetically predisposed multifactorial disorders. Exploration of the genetic co-drivers toward AA and AD was performed with Mendelian randomization with genome-wide association studies.2 The approach identified IL-13 as one of the top associated single nucleotide polymorphisms.2 IL-13 would be a therapeutic target molecule for typical atopic AA. Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone and prevents its interaction with the receptor and subsequent downstream signaling.3 Tralokinumab is currently appliable for moderate-to-severe refractory AD. In this issue of the International Journal of Dermatology, Tavoletti et al.4 reported on the effectiveness of tralokinumab for refractory AD and AA associated with AD. The application of tralokinumab to treat the 33-year-old female patient featured in this report achieved clinical remission of AD (EASI score: from 24 to 2) and almost complete hair regrowth within the timespan of 6 months (SALT score: from 22 to 2 and the alopecia areata investigator's global assessment score: from 3/5 to 1/5), also demonstrating great improvement of her QoL (Dermatology Life Quality Index score: from 13 to 4).4 This would be the first reported case showing the effectiveness of tralokinumab for AA associated with AD. Currently, baricitinib, Janus kinase (JAK) 1/2 inhibitor, and ritlecitinib, JAK3/ tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, are appliable for moderate-to-severe refractory AA. Current alternative therapeutic options in the management of AA represent JAK inhibitors (ruxolitinib and tofacitinib), a phosphodiesterase-4 inhibitor (apremilast), and biologics (aldesleukin, dupilumab and secukinumab).5 Tralokinumab and dupilumab probably have particular potency to induce hair regrowth and to improve QoL impairment for atopic AA with high total serum IgE levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAlopecia AreataHumansInterleukin-13Antibodies, Monoclonal, Humanized

Substanzen

Interleukin-13Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Kindai University Nara Hospital, Ikoma, Japan.

ORCID-Profile: Naoki Oiso

Zitieren

APA

Oiso, N. (2024). Interleukin‐13 as a promising therapeutic target for alopecia areata associated with atopic dermatitis. International Journal of Dermatology. https://doi.org/10.1111/ijd.17053

Vancouver

Oiso N. Interleukin‐13 as a promising therapeutic target for alopecia areata associated with atopic dermatitis. International Journal of Dermatology. 2024. doi:10.1111/ijd.17053

BibTeX
@article{Oiso2024,
  author = {Oiso, Naoki},
  title = {Interleukin‐13 as a promising therapeutic target for alopecia areata associated with atopic dermatitis},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17053}
}
Kostenlos starten →